Sensorion to Attend the American Society of Gene & Cell Therapy (ASGCT) and Gene Therapy Analytical Development Conferences in May 2022
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, is pleased to announce the participation of Sensorion’s management in two scientific conferences being held in May 2022.
Patrice Vidal, Sensorion’s Group Leader – Technology & Innovation Platform, will present a poster entitled “Adeno-Associated Vector Discovery Platform for Inner Ear Disorders”, on May 18, 2022, at the American Society of Gene and Cell Therapy’s (ASGCT) 25th Annual Meeting, taking place on May 16-19, 2022. An abstract is accessible on the ASGCT website (link to access the abstract).
Date: Wednesday May 18, 2022
Presentation: 5:30 pm – 6:30 pm EDT (11:30 pm – 12:30 pm CEST)
Event: American Society of Gene and Cell Therapy Annual Meeting (ASGCT)
Christine Le Bec, Sensorion’s Head of CMC Gene Therapy, will give a presentation, in-person, entitled “Developing Functional Analytical Assays for the Characterisation of Dual AAVs”, on May 31, 2022, at the Gene Therapy Analytical Development, taking place on May 30 – June 1, 2022 in London, United Kingdom.
Date: Tuesday May 31, 2022
Presentation: 9:30 am – 10am EDT (2:30 pm – 3 pm UK Time)
Event: Gene Therapy Analytical Development
Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need.
Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and modalities for drug candidates. Its portfolio combines both small molecule programs and a preclinical portfolio of inner ear gene therapies.
Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 Proof of Concept study of SENS-401 clinical study in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, a study of SENS-401 in patients scheduled for cochlear implantation.
Sensorion has entered into a broad strategic collaboration with Institut Pasteur focused on the genetics of hearing. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness caused by a mutation of the gene encoding for Otoferlin, and hearing loss related to mutation in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses.
This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2021 full year financial report published on April 28, 2022, and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.
Head of Investor Relations & Communication
+ 33 6 72 18 00 22
International Media Relations
Mary-Jane Elliott/Jessica Hodgson
+ 44 7739 788014+44 7561 424788